The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
April 19th 2024
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Taking a Critical Look at Healthcare Inequity Among Patients with Cancer: What Role Do Onco-Nurses Play?
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
FDA Approves Ready-to-Dilute Cyclophosphamide Injection for Various Cancers
The FDA has approved a new drug application for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy in the treatment of patients with various types of cancers, including malignant lymphoma, multiple myeloma, and various types of leukemia.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma
June 26th 2023Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.
Dr Bal on the Investigation of BMS-986393 in R/R Multiple Myeloma
June 21st 2023Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.
Dr Costa on MRD-Modulated Post-ASCT Quadruplet Induction in Newly Diagnosed Multiple Myeloma
June 21st 2023Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.
Cilta-Cel Demonstrates Long-Term PFS, Safety in R/R Multiple Myeloma
Administration of a single infusion of ciltacabtagene autoleucel prolonged progression-free survival, generated sustained responses, and continued to demonstrate a manageable safety profile in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to final results from the phase 1b/2 CARTITUDE-1 study.
DaraVCD Elicits Responses in Multiple Myeloma With Extramedullary Disease
June 9th 2023The combination of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone, elicited a complete response (CR) rate of 40% and a CR or better rate of 43% in patients with multiple myeloma presenting with extramedullary disease.
Daratumumab Maintenance Is Safe, Feasible After Salvage Transplant in Multiple Myeloma
June 9th 2023Daratumumab maintenance therapy with or without pomalidomide provided a tolerable and feasible treatment option after salvage hematopoietic stem cell transplantation in patients with relapsed multiple myeloma.
Teclistamab Data Show Sustained Benefit in Relapsed/Refractory Multiple Myeloma
June 9th 2023Teclistamab continued to elicit deep and durable responses in patients with relapsed/refractory multiple myeloma, irrespective of being triple-class refractory, daratumumab-refractory, or refractory to last line of therapy.
Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma
June 9th 2023The addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple myeloma who were able to meet their stem cell collection goals on first attempt.
Daratumumab Plus Ixazomib and Dexamethasone Produces Significant Responses in R/R Multiple Myeloma
June 9th 2023The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial.
FDA Lifts Partial Clinical Hold on Phase 1 Trial of MT-0169 in Multiple Myeloma, Hodgkin Lymphoma
The FDA has removed a partial clinical hold that had been placed on a phase 1 trial investigating the safety and efficacy of MT-0169 as a potential therapeutic option in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.
Cilta-cel Possesses Potential to Be New SOC for Lenalidomide-refractory Myeloma After First Relapse
Ciltacabtagene autoleucel significantly improved progression-free survival over standard-of-care pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.